Reduction in saturated fat intake for cardiovascular disease: Evidence and implications for public health

Review Focus

**P** Adults (18 years or older) with or without cardiovascular disease

**I** Dietary advice, supplementation of fats, oils, modified or low-fat foods, or a provided diet

**C** Usual diet, placebo, or a controlled diet

**O** Primary Outcomes: All-cause mortality, cardiovascular mortality, combined cardiovascular disease (CVD) events

Secondary Outcomes: Additional health events, blood measures, adverse effects reported by study authors

Review Quality Rating: 10 (strong) Details on the methodological quality are available [here](#).

Considerations for Public Health Practice

**Conclusions from Health Evidence™**

This systematic review and meta-analysis includes 15 randomized controlled trials (RCTs) and 17 comparisons with a total of 59,000 participants. There is moderate quality evidence for all primary and secondary outcomes, except for the secondary outcome coronary heart disease events, which is a synthesis of low-quality evidence.

**Primary Outcomes**

- Long-term trials found that reducing dietary saturated fat is associated with a small but important reduction in cardiovascular risk, 17% (4%-28%)
- Reducing saturated fat has no effect on all-cause mortality or cardiovascular mortality compared to usual diet

**Secondary Outcomes**

- Reducing saturated fat has no significant effect on lowering risk of myocardial infarctions, non-fatal myocardial infarctions, stroke, or coronary heart disease
- Replacing saturated fat with polyunsaturated fat (and not monounsaturated fat, carbohydrates or protein) reduces the risk of cardiovascular events by 27%

**General Implications**

Public Health should focus on interventions aiming to reduce saturated fat intake for durations of up to 52 months to lower the risk of cardiovascular events in adults with or without CVD.

Public Health should be aware and consider that interventions to reduce saturated fat intake are not effective in reducing all-cause mortality, cardiovascular mortality, risk of myocardial infarction, stroke, or coronary heart disease mortality and events.

Public Health should consider implementing interventions that promote polyunsaturated fats in place of saturated fats to reduce the risk of cardiovascular events.

Date this evidence summary was written: June 2016
### Evidence and Implications

<table>
<thead>
<tr>
<th>What's the evidence?</th>
<th>Implications for practice and policy</th>
</tr>
</thead>
</table>
| **1. Primary Outcome: Cardiovascular Events (11 RCTs [13 comparisons], 53,300 participants)** | **1. Primary Outcome: Cardiovascular Events**  
- Reducing saturated fat intake reduces cardiovascular events by 17% (RR 0.83; 95% CI 0.72 to 0.96; 13 trials; 53,300 participants; **moderate** quality evidence)  
- To reduce the risk of combined cardiovascular events, Public Health should promote interventions to reduce and/or modify dietary saturated fat intake.  
- Intervention durations up to 52 months are effective, compared to no intervention/usual saturated fat intake. |
| **2. Primary Outcome: All-cause Mortality (11 RCTs [12 comparisons], 55,858 participants)** | **2. Primary Outcome: All-cause Mortality**  
- Reducing saturated fat has no effect on all-cause mortality (RR 0.97; 95% CI 0.90 to 1.05; 3,276 deaths; **moderate** quality evidence)  
- Public Health should be aware that interventions to reduce saturated fat intake are not effective in reducing all-cause mortality among people identified at risk of CVD. |
| **3. Primary Outcome: Cardiovascular Mortality (10 RCTs [12 comparisons], 53,421 participants)** | **3. Primary Outcome: Cardiovascular Mortality**  
- Reducing saturated fat has no effect on cardiovascular mortality (RR 0.95; 95% CI 0.80 to 1.12; 12 trials; 53,421 participants; **moderate** quality evidence)  
- Public Health should be aware that interventions to reduce saturated fat intake are not effective in reducing cardiovascular mortality. |
| **4. Secondary Outcomes:**  
Myocardial Infarctions (MI) (10 RCTs [11 comparisons], 53,167 participants) | **4. Secondary Outcomes**  
- Reducing saturated fat intake has no effect on myocardial infarction (RR 0.90; 95% CI 0.80 to 1.01; 11 trials; 53,167 participants; **moderate** quality evidence)  
- Public Health should note that reducing saturated fat is not effective for reducing the risk of myocardial infarctions, stroke, or coronary heart disease mortality and events.  
- Reducing saturated fat has no effect on reducing the risk of non-fatal myocardial infarctions (RR 0.95; 95% CI 0.80 to 1.13; 9 trials; 52,834 participants; **moderate** quality evidence)  
- Reducing saturated fat has no effect on risk of stroke (RR 1.00; 95% CI 0.89 to 1.12; 8 trials; 50,952 participants; **moderate** quality evidence)  
- Reducing saturated fat intake has no effect on CHD mortality risk (RR 0.98; 95% CI 0.84 to 1.15; 10 trials; 53,159 participants; **moderate** quality evidence)  
- Reducing saturated fat has no effect on CHD events (RR 0.87; 95% CI 0.74 to 1.03; 12 trials; 53,199 participants; **low** quality evidence) |
**5. Subgroup Analysis: Replacing saturated fat with polyunsaturated fat, carbohydrates, protein, or monounsaturated fats**

<table>
<thead>
<tr>
<th>Subgroup</th>
<th>Effect on Cardiovascular Events</th>
<th>Relative Risk</th>
<th>Confidence Interval</th>
<th>Quality Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturated fat with polyunsaturated fat</td>
<td>No effect</td>
<td>0.98</td>
<td>0.58 to 0.92</td>
<td>Moderate</td>
</tr>
<tr>
<td>Saturated fat with monounsaturated fat</td>
<td>No effect</td>
<td>1.00</td>
<td>0.53 to 1.89</td>
<td>Very Low</td>
</tr>
<tr>
<td>Saturated fat with carbohydrates</td>
<td>No effect</td>
<td>0.93</td>
<td>0.79 to 1.08</td>
<td>Low</td>
</tr>
<tr>
<td>Saturated fat with protein</td>
<td>No effect</td>
<td>0.90</td>
<td>0.90 to 1.06</td>
<td>Moderate</td>
</tr>
</tbody>
</table>

**Legend:**
- P – Population
- I – Intervention
- C – Comparison group
- O – Outcomes
- CI – Confidence Interval
- OR – Odds Ratio
- RR – Relative Risk
- MD – Mean Difference

**Subgroup Analysis:**

- For interventions aiming to reduce CVD events, Public Health should promote replacing saturated fat with polyunsaturated fat.
- Public Health should use caution in suggesting or promoting saturated fat replacements (i.e., monounsaturated fat, carbohydrates, protein) for reducing the risk of CVD events as evidence suggests this is not effective and/or evidence is limited.

---

### Why this issue is of interest to public health:

Cardiovascular disease (CVD) is a leading cause of death among Canadians, attributable to approximately 32% of deaths. Nearly $22.2 billion is spent treating and managing CVD annually, with disease expenditures expected to rise. The World Health Organization states that CVD risk factors can be reduced through stress management, healthy eating, regular physical activity, and maintaining a healthy weight.

Increased fruit and vegetable intake and decreased fat intake are effective and/or evidence is limited.

Replacing saturated fat with polyunsaturated fat, carbohydrates, protein, or monounsaturated fats is recommended for preventing CVD. The recommended daily fat intake for adults is between 20% and 35% of total caloric intake; however, 25% of males and 23% of females have fat intakes above the acceptable macronutrient distribution range. High intake of saturated fat elevates low density lipoprotein cholesterol levels in the blood and increases risk of cardiovascular disease and cardiovascular events.

Due to the sizeable health concerns related to the consumption of saturated fats, it is important for public health to consider effective interventions to modify dietary fat intake in adults.

---

### Other quality reviews on this topic are available on [www.healthevidence.org](http://www.healthevidence.org).

### Suggested citation:


This evidence summary was written to condense the work of the authors of the review referenced on page one. The intent of this summary is to provide an overview of the findings and implications of the full review. For more information on individual studies included in the review, please see the review itself.

The opinion and ideas contained in this document are those of the evidence summary author(s) and healthevidence.org. They do not necessarily reflect or represent the views of the author’s employer or other contracting organizations. Links from this site to other sites are presented as a convenience to healthevidence.org internet users. Healthevidence.org does not endorse nor accept any responsibility for the content found at these sites.